Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares.

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...

Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into ...

A New York appellate court on Tuesday denied President-elect Donald Trump's bid to halt sentencing set for Friday for his conviction on criminal charges stemming from hush money paid to a porn ...

Ukraine's air force says one of its F-16 fighter jet pilots shot down six missiles during a Russian aerial attack last month. Meanwhile, Moscow says its troops have inflicted a series of defeats ...

A force fighting Sudan’s army in a brutal civil war committed massacres and rape that amount to genocide, the Secretary of State said, two decades after a finding of genocide in the same region ...